Print  |  Close

Barry D. Luskey MD

Barry D. Luskey MD

Summit Cancer Care

Education and Training

Medical School: University of Texas Southwestern Medical, Dallas, Texas

Internship: Brigham & Women's Hospital, Boston, Massachusetts

Residency: Brigham & Women's Hospital, Boston, Massachusetts

Fellowship: Brigham & Women's Hospital, Boston, Massachusetts, The Children's Hospital, Boston, Massachusetts

Specialty and Certification

Medical Oncology, Hematology / Board Certified

Clinical Trial Cancer Types

Breast Cancer, Colon/Rectal Cancer, Gynecologic Cancers, Head and Neck Cancer, Hematopoietic Malignancies, Leukemia, Lung Cancer, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian Cancer, Plasma cell neoplasm, Primary Peritoneal Cancer, Prostate Cancer , Quality of Life, Solid Tumor

Affiliations

St. Joseph's/Candler

Active Clinical Trial Sites in Georgia

Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center

4700 Waters Avenue
Savannah, GA 31404
912-350-8490 (p)
www.memorialhealth.com/anderson-cancer-institute.aspx

driving directions

Clinical Trials


DeKalb Surgical Associates - Northside

980 Johnson Ferry Road, NE
Suite 430
Atlanta, GA 30342
404-508-4320 (p)
404-508-4112 (f)
www.dekalbsurgical.com

driving directions

Clinical Trials


Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler

225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org

driving directions

Clinical Trials
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Cancer Type: Breast Cancer

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Breast Cancer

T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type: Breast Cancer

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Breast Cancer

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Breast Cancer

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Breast Cancer

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Breast Cancer

Adding an Immunotherapy Drug, MEDI4736 (durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Cancer Type: Breast Cancer

An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control

An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
Cancer Type: Colon/Rectal Cancer

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Gynecologic Cancers

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Hematopoietic Malignancies

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Leukemia

Financial Difficulty in Patients with Blood Cancer
Cancer Type: Leukemia

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer

Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type: Lung Cancer

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type: Lung Cancer

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Lung Cancer

Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type: Lung Cancer

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients who are PD-L1 Negative
Cancer Type: Lung Cancer

Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Trial
Cancer Type: Lung Cancer

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer

An Observational Research Study to Uncover Subtypes of Cancer Cachexia, LOTUS-CC Study
Cancer Type: Lung Cancer

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma

Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cancer Type: Melanoma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Multiple Myeloma

Financial Difficulty in Patients with Blood Cancer
Cancer Type: Multiple Myeloma

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Non-Hodgkin Lymphoma

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Plasma cell neoplasm

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Plasma cell neoplasm

Financial Difficulty in Patients with Blood Cancer
Cancer Type: Plasma cell neoplasm

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Primary Peritoneal Cancer

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Prostate Cancer

Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Prostate Cancer

Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life

National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Solid Tumor

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type: Solid Tumor

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Cancer Type: Solid Tumor

Use of a Genomic Tumor Board to Increase the Number of Patients with Recurrent, Refractory, Metastatic, or Newly Diagnosed Advanced Solid Tumors who Receive Genome-Informed Treatment
Cancer Type: Solid Tumor

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Solid Tumor

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Cancer Type: Solid Tumor

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Unknown Primary

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Unknown Primary

Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Unknown Primary

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Unknown Primary

Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Unknown Primary

Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type: Unknown Primary

Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Unknown Primary

Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type: Unknown Primary

Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Unknown Primary

Use of a Genomic Tumor Board to Increase the Number of Patients with Recurrent, Refractory, Metastatic, or Newly Diagnosed Advanced Solid Tumors who Receive Genome-Informed Treatment
Cancer Type: Unknown Primary

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Unknown Primary

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Unknown Primary

Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Unknown Primary


Summit Cancer Care - Statesboro

16741 Highway 67 South
Suite B
Statesboro, GA 30458
912-871-8837 (p)
www.summitcancercare.com

driving directions

Clinical Trials


Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion

225 Candler Drive
Suite 300
Savannah, GA 31405
912-354-6187 (p)
www.summitcancercare.com

driving directions

Clinical Trials

Active Clinical Trial Site Locations:

**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.